Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Background Recent cardiovascular outcome trials have shown that sodium–glucose co-
transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in …

Background Chronic kidney disease and heart failure are insulin resistant states associated
with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type …

OBJECTIVE In patients with moderate to severe albuminuric kidney disease, sodium–
glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post …

Importance Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal
glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart …

Background Dapagliflozin's antihyperglycemic effects are mediated by inhibition of renal
sodium-glucose cotransporter-2; therefore, renal safety of dapagliflozin was assessed …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

Abstract Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …